Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?

Literature DB >> 10398452

What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?

Abstract

Entities: Disease

Year: 1996 PMID： 10398452 DOI： 10.1002/(SICI)1099-1654(199606)6:2<97::AID-RMV168>3.0.CO;2-4

Source DB: PubMed Journal: Rev Med Virol ISSN： 1052-9276 Impact factor: 6.989

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

1. Inhibition of the activity of recombinant HIV-1 integrase by derivatives of higher terpenoids.

Authors: E A Semenova; O A Plyasunova; N I Petrenko; N V Uzenkova; E E Shul'ts; G A Tolstikov; A G Pokrovskii
Journal: Dokl Biochem Biophys Date: 2003 Jul-Aug Impact factor: 0.788

2. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.

Authors: H Pelemans; R Esnouf; A Dunkler; M A Parniak; A M Vandamme; A Karlsson; E De Clercq; J P Kleim; J Balzarini
Journal: J Virol Date: 1997-11 Impact factor: 5.103

3. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2.

Authors: R W Buckheit; K Watson; V Fliakas-Boltz; J Russell; T L Loftus; M C Osterling; J A Turpin; L A Pallansch; E L White; J W Lee; S H Lee; J W Oh; H S Kwon; S G Chung; E H Cho
Journal: Antimicrob Agents Chemother Date: 2001-02 Impact factor: 5.191

4. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.

Authors: R M Esnouf; J Ren; A L Hopkins; C K Ross; E Y Jones; D K Stammers; D I Stuart
Journal: Proc Natl Acad Sci U S A Date: 1997-04-15 Impact factor: 11.205

5. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.

Authors: R W Buckheit; E L White; V Fliakas-Boltz; J Russell; T L Stup; T L Kinjerski; M C Osterling; A Weigand; J P Bader
Journal: Antimicrob Agents Chemother Date: 1999-08 Impact factor: 5.191

6. 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.

Authors: M Witvrouw; M E Arranz; C Pannecouque; R Declercq; H Jonckheere; J C Schmit; A M Vandamme; J A Diaz; S T Ingate; J Desmyter; R Esnouf; L Van Meervelt; S Vega; J Balzarini; E De Clercq
Journal: Antimicrob Agents Chemother Date: 1998-03 Impact factor: 5.191

7. Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1.

Authors: G M Szczech; P Furman; G R Painter; D W Barry; K Borroto-Esoda; T B Grizzle; M R Blum; J Sommadossi; R Endoh; T Niwa; M Yamamoto; C Moxham
Journal: Antimicrob Agents Chemother Date: 2000-01 Impact factor: 5.191